Pediatric Dubin-Johnson Syndrome 

  • Author: Simon S Rabinowitz, MD, PhD; Chief Editor: Carmen Cuffari, MD   more...
 
Updated: May 4, 2010
 

Background

First described in 1954,[1] Dubin-Johnson syndrome (DJS) is an inherited, relapsing, benign disorder of bilirubin metabolism.[2] This rare autosomal recessive condition is characterized by conjugated hyperbilirubinemia with normal liver transaminases, a unique pattern of urinary excretion of heme metabolites (coproporphyrins), and the deposition of a pigment that gives the liver a characteristic black color (see the image below).

Gross liver specimen from a patient with Dubin-JohGross liver specimen from a patient with Dubin-Johnson syndrome showing multiple areas of dark pigmentation. Image courtesy of Cirilo Sotelo-Avila, MD.

The primary defect in Dubin-Johnson syndrome is a mutation in an apical canalicular membrane protein responsible for excretion of bilirubin, and other nonbile salt organic anions. Originally termed the canalicular multiple organic anion transporter (cMOAT), it is also known as multidrug resistance protein 2 (MRP2) and is a member of the ABC transporter superfamily.[3, 4, 5] The gene that encodes the transporter is ABCC2 and is found on chromosome 10.

Clinical onset is most often seen in early adulthood; however, a neonatal onset has also been rarely described. Because of possible recurrence and second attacks of jaundice in later life, the neonatal form requires closer long term follow-up.[6]

Four inherited defects in bilirubin metabolism are recognized. Gilbert syndrome and Crigler-Najjar syndrome are associated with indirect hyperbilirubinemia. The other syndromes, Dubin-Johnson syndrome and Rotor syndrome, result in conjugated hyperbilirubinemia. Only Dubin-Johnson syndrome has the melaninlike pigment in the liver cells and increased urinary coproporphyrin I. Both inherited direct hyperbilirubinemias have a relatively benign course. However, diagnosing these conditions allows the physician to exclude other more serious causes of hyperbilirubinemia and, thus, avoid unnecessary investigations and procedures.

Next

Pathophysiology

The conjugated hyperbilirubinemia observed in Dubin-Johnson syndrome results from defective transport of bilirubin glucuronide across the membrane that separates the hepatocyte from the bile canaliculi. Pigment that is not secreted from the hepatocyte is stored in the lysosome and causes the black liver color.[7] A hallmark of Dubin-Johnson syndrome, the mechanism of which is not fully understood, is a reversal of the usual ratio between the byproducts of heme biosynthesis: urinary coproporphyrin I levels are higher than coproporphyrin III levels. In unaffected individuals, the ratio of coproporphyrin III to coproporphyrin I is approximately 3-4:1.[8, 9]

The cMOAT/MRP2 protein is encoded by a single-copy gene located on chromosome 10q24.[10] MRP2 plays an important role in the detoxification of many drugs by transporting a wide range of compounds, especially conjugates of glutathione, glucuronate, and sulfate, which are collectively known as phase II products of biotransformation. Unlike other members of the MRP/ABCC family, MRP2 is only expressed on the apical membrane domain of polarized cells. Besides hepatocytes, it is located in renal proximal tubular cells, enterocytes, and syncytiotrophoblasts of the placenta.[11] Energy derived from ATP is critical to the secretory function of MRP2. Mutations in the ATP-binding region represent a significant proportion of the recognized genetic defects in Dubin-Johnson syndrome.

An enhanced understanding of the molecular biology of Dubin-Johnson syndrome is derived from investigations of the missense mutation Delta (R,M).[12] This leads to the loss of 2 amino acids from the second ATP-binding domain of MRP2. The mutated MRP2 Delta (R,M) is associated with the absence of the MRP2 glycoprotein from the apical membrane of hepatocytes. In this mutation, only core glycosylation of the protein occurs, which interferes with transport from the endoplasmic reticulum to the canalicular membrane of the hepatocyte. The mutated protein is sensitive to endoglycosidase H digestion in the endoplasmic reticulum. Proteasomes are also involved in the degradation of the mutated protein.

Previous
Next

Epidemiology

Frequency

United States

Overall prevalence of Dubin-Johnson syndrome is extremely low. Although no accurate prevalence figures are available, Dubin-Johnson syndrome is far more common than Rotor syndrome.

International

The highest recognized prevalence (1 case per 1300 population) is in Iranian Jews and is clustered in the same families.[13] The prevalence in Moroccan Jews is nearly as high, a reflection of the fact that these populations diverged about 2000–2500 years ago.[14]

Mortality/Morbidity

For the most part, patients are asymptomatic and have normal life spans. Jaundice is the most consistent finding in patients with Dubin-Johnson syndrome. Some neonates can present with cholestasis, which may be severe. Increased fetal wastage has been reported in one study.[15]

Race

In persons of Iranian Jewish descent, prevalence is primarily increased because of cultural pressures that support isolation and, therefore, consanguineous marriages and reproduction trends.

Sex

Dubin-Johnson syndrome occurs in both sexes, but some authors have reported increased incidence and earlier onset in males.[13, 16, 17]

Age

Dubin-Johnson syndrome is rarely detected before puberty, although neonatal cases have been reported. It is most often diagnosed in the late teens and early adulthood.

Previous
 
 
Contributor Information and Disclosures
Author

Simon S Rabinowitz, MD, PhD  Professor of Clinical Pediatrics, New York Medical College; Chairman, Chief and Medical Administrator, Department of Pediatrics, Chief, Pediatric Gastroenterology and Nutrition, Richmond University Medical Center

Simon S Rabinowitz, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Gastroenterology, American Gastroenterological Association, American Medical Association, New York Academy of Sciences, North American Society for Pediatric Gastroenterology and Nutrition, Phi Beta Kappa, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Hamza Elkhidir, MBBS  Staff Physician, Department of Pediatrics, Richmond University Medical Center

Hamza Elkhidir, MBBS is a member of the following medical societies: Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Suzanne M Carter, MS  Senior Genetic Counselor, Associate, Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Montefiore Medical Center, Albert Einstein College of Medicine

Suzanne M Carter, MS is a member of the following medical societies: American Bar Association

Disclosure: Nothing to disclose.

Susan J Gross, MD, FRCS(C), FACOG, FACMG  Codirector, Division of Reproduction Genetics, Associate Professor, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine

Susan J Gross, MD, FRCS(C), FACOG, FACMG is a member of the following medical societies: American College of Medical Genetics, American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, American Society of Human Genetics, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

Hisham Nazer, MB, BCh, FRCP, DCh, DTM&H  Professor of Pediatrics, Consultant in Pediatric Gastroenterology, Hepatology and Clinical Nutrition, Bushnaq Medical Centre, University of Jordan

Hisham Nazer, MB, BCh, FRCP, DCh, DTM&H is a member of the following medical societies: Royal College of Paediatrics and Child Health, Royal College of Physicians, Royal College of Surgeons in Ireland, Royal College of Surgeons of Edinburgh, and Royal Society of Tropical Medicine and Hygiene

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Steven M Schwarz, MD, FAAP, FACN, AGAF  Professor of Pediatrics, Children's Hospital at Downstate, SUNY-Downstate Medical Center

Steven M Schwarz, MD, FAAP, FACN, AGAF is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, American Gastroenterological Association, American Pediatric Society, Gastroenterology Research Group, New York Academy of Medicine, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research

Disclosure: Curemark, LLC Consulting fee Board membership; Centocor, Inc. Grant/research funds Independent contractor; Johnson & Johnson, Inc. Grant/research funds Independent contractor

Chief Editor

Carmen Cuffari, MD  Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References
  1. Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore). Sep 1954;33(3):155-97. [Medline].

  2. Habashi SL, Lambiase L R. Dubin-Johnson Syndrome. eMedicine from WebMD [serial online]. October 2006;Available at http://emedicine.medscape.com/article/173517-overview.

  3. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology. Jun 1997;25(6):1539-42. [Medline].

  4. Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet. Mar 1999;64(3):739-46. [Medline].

  5. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr. Dec 2001;33(6):493-501. [Medline].

  6. Kimura A, Ushijima K, Kage M, et al. Neonatal Dubin-Johnson syndrome with severe cholestasis: effective phenobarbital therapy. Acta Paediatr Scand. Mar 1991;80(3):381-5. [Medline].

  7. Muscatello U, Mussini I, Agnolucci MT. The Dubin-Johnson syndrome: an electron microscopic study of the liver cell. Acta Hepatosplenol. May-Jun 1967;14(3):162-70. [Medline].

  8. Koskelo P, Toivonen I, Adlercreutz H. Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome. Clin Chem. Nov 1967;13(11):1006-9. [Medline].

  9. Frank M, Doss M, de Carvalho DG. Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. Hepatogastroenterology. Feb 1990;37(1):147-51. [Medline].

  10. van Kuijck MA, Kool M, Merkx GF, et al. Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet. 1997;77(3-4):285-7. [Medline].

  11. Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. Jun 2006;2(3):351-66. [Medline].

  12. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology. Dec 2000;32(6):1317-28. [Medline].

  13. Zlotogora J. Hereditary disorders among Iranian Jews. Am J Med Genet. Jul 31 1995;58(1):32-7. [Medline].

  14. Mor-Cohen R, Zivelin A, Fromovich-Amit Y, Kovalski V, Rosenberg N, Seligsohn U. Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations. Blood Coagul Fibrinolysis. Mar 2007;18(2):139-44. [Medline].

  15. Di Zoglio JD, Cardillo E. The Dubin-Johnson syndrome and pregnancy. Obstet Gynecol. Oct 1973;42(4):560-3. [Medline].

  16. Dubin IN. Chronic idiopathic jaundice; a review of fifty cases. Am J Med. Feb 1958;24(2):268-92. [Medline].

  17. Shani M, Seligsohn U, Gilon E, Sheba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med. Oct 1970;39(156):549-67. [Medline].

  18. Respaud R, Benz-de Bretagne I, Blasco H, et al. Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of multidrug resistance protein 2 (MRP2) function in humans. J Chromatogr B Analyt Technol Biomed Life Sci. Nov 15 2009;877(30):3893-8. [Medline].

  19. Rocchi E, Balli F, Gibertini P, Trenti T, et al. Coproporphyrin excretion in healthy newborn babies. J Pediatr Gastroenterol Nutr. Jun 1984;3(3):402-7. [Medline].

  20. Mayatepek E, Lehmann WD. Defective hepatobiliary leukotriene elimination in patients with the Dubin-Johnson syndrome. Clin Chim Acta. May 30 1996;249(1-2):37-46. [Medline].

  21. Bar-Meir S, Baron J, Seligson U, Gottesfeld F, Levy R, Gilat T. 99mTc-HIDA cholescintigraphy in Dubin-Johnson and Rotor syndromes. Radiology. Mar 1982;142(3):743-6. [Medline].

  22. Shimizu T, Tawa T, Maruyama T, Oguchi S, Yamashiro Y, Yabuta K. A case of infantile Dubin-Johnson syndrome with high CT attenuation in the liver. Pediatr Radiol. Apr 1997;27(4):345-7. [Medline].

  23. Kitamura T, Alroy J, Gatmaitan Z, et al. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology. Jun 1992;15(6):1154-9. [Medline].

  24. Regev RH, Stolar O, Raz A, Dolfin T. Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid. J Perinat Med. 2002;30(2):185-7. [Medline].

  25. Arias IM, Blumberg W. The pigment in Dubin-Johnson syndrome. Gastroenterology. Oct 1979;77(4 Pt 1):820-1. [Medline].

  26. Hashimoto K, Uchiumi T, Konno T, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology. Nov 2002;36(5):1236-45. [Medline].

  27. Tate G, Li M, Suzuki T, Mitsuya T. A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Genes Genet Syst. Apr 2002;77(2):117-21. [Medline].

Previous
Next
 
Gross liver specimen from a patient with Dubin-Johnson syndrome showing multiple areas of dark pigmentation. Image courtesy of Cirilo Sotelo-Avila, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.